Abstract
Objective: In VOYAGE-1, guselkumab(GUS) was evaluated in moderate-to-severe plaque psoriasis. In Year-1, greater proportions of GUS-treated patients vs adalimumab(ADA) achieved optimal patient-reported outcomes(PRO) of being symptom- and sign-free as well as demonstrating normal HRQoL. Here, in a post hoc analysis, we present PROs for GUS-treated patients for up to 5-years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
